CareDx, Inc. (NASDAQ:CDNA) Given Consensus Rating of "Hold" by Brokerages
CareDx, Inc. (NASDAQ:CDNA) has received a consensus "Hold" rating from nine research firms. Five analysts recommend holding the stock, while four suggest buying. The average 12-month price target is $26.00. Recent analyst actions include Zacks Research upgrading the stock to "Hold" and Wells Fargo lowering its price target to $14.00. CareDx's recent earnings exceeded expectations, with a net margin of 17.97% and revenue up 20.7% year-over-year.
CareDx, Inc. (NASDAQ:CDNA - Get Free Report) has been given a consensus recommendation of "Hold" by the nine research firms that are presently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $26.00.
A number of equities research analysts have issued reports on the stock. Zacks Research raised shares of CareDx from a "strong sell" rating to a "hold" rating in a report on Tuesday, November 18th. Wells Fargo & Company decreased their price objective on CareDx from $19.00 to $14.00 and set an "equal weight" rating on the stock in a research note on Friday, August 8th. William Blair assumed coverage on CareDx in a research note on Tuesday, August 26th. They issued a "market perform" rating for the company. BTIG Research upped their price target on CareDx from $22.00 to $25.00 and gave the company a "buy" rating in a research report on Thursday, November 6th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of CareDx in a report on Tuesday.
View Our Latest Report on CDNA
Institutional Trading of CareDx
Several institutional investors and hedge funds have recently modified their holdings of the business. MCF Advisors LLC grew its holdings in shares of CareDx by 292.9% during the second quarter. MCF Advisors LLC now owns 1,336 shares of the company's stock worth $26,000 after purchasing an additional 996 shares in the last quarter. Allworth Financial LP purchased a new position in CareDx in the 2nd quarter worth approximately $40,000. State of Alaska Department of Revenue bought a new position in shares of CareDx in the 3rd quarter worth $43,000. PNC Financial Services Group Inc. raised its position in shares of CareDx by 20,200.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,466 shares of the company's stock valued at $79,000 after buying an additional 4,444 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of CareDx during the 3rd quarter valued at $89,000.
CareDx Stock Performance
Shares of CareDx stock opened at $17.81 on Thursday. The stock has a market capitalization of $916.02 million, a P/E ratio of 17.46 and a beta of 2.50. CareDx has a 52-week low of $10.96 and a 52-week high of $26.37. The stock's 50-day simple moving average is $15.30 and its 200 day simple moving average is $15.60.
CareDx (NASDAQ:CDNA - Get Free Report) last posted its earnings results on Tuesday, November 4th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.15. CareDx had a net margin of 17.97% and a return on equity of 18.03%. The firm had revenue of $100.06 million during the quarter, compared to the consensus estimate of $95.25 million. During the same quarter last year, the company earned ($0.14) earnings per share. The company's revenue was up 20.7% on a year-over-year basis. CareDx has set its FY 2025 guidance at EPS. Equities research analysts forecast that CareDx will post -0.9 EPS for the current fiscal year.
CareDx Company Profile
(Get Free Report)CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Further Reading
- Five stocks we like better than CareDx
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Why Gold Loves Trump as Much as Trump Loves Gold
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Google's Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage
- Short Selling - The Pros and Cons
- Palantir Isn’t Just Riding the AI Boom—It’s Orchestrating It
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in CareDx Right Now?
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
